HALO – Halozyme Therapeutics Inc

Originally published on May 26, 2022

Background

While Halozyme was originally founded in 1998 and subsequently went public in 2004, the dramatic catalyst that transformed the company occurred in 2019, following a major restructuring off the back of a spectacular failure of its pancreatic cancer candidate, PEGPH20. Before November 2019, most of Halozyme’s research and development activities …